Extension of PrescribeIT Exemption

The TPP Alberta Steering Committee convened on September 26, 2024, to engage with representation from PrescribeIT. In this meeting, we reviewed the status of electronic medical record (EMR) vendor systems integrated with PrescribeIT to include a structured, mandatory “Indication for Use” input field.

Initially, the Steering Committee had set September 30, 2024, as the compliance deadline for the EMR vendors to implement the mandatory field. After extensive discussion, we voted to extend this exemption period to meet all functional requirements for prescribing TPP-monitored medications to June 30, 2025. Please note that no further extension requests will be accepted beyond this date.

A mandatory “Indication for Use” field for TPP Type 1 medications means that prescriptions will not be transmitted from the EMR unless this information is inputted, and instead, an error message will appear. This requirement aims to enhance data quality and ensure compliance within the PrescribeIT system. 

During this interim period, it remains the expectation to include indication for use information when prescribing TPP Type 1 medications.

Questions? Please feel free to contact TPP Alberta at tpp.info@cpsa.ab.ca.